Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOB015 in Distal Subungual Onychomycosis
NCT01246518Phase 2Completed
- Sponsor
- Moberg Pharma AB
- Start
- Dec 2010
- Primary completion
- Oct 2012
- Modality
- Transdermal Patches, Orthosteric Ligands, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MOB-015 in onychomycosis (2 arms), sponsored by Moberg Pharma AB. Primary endpoint: Mycological cure of target nail at 12 months. Started Dec 2010; status: completed.
02
Drugs
MOB-015
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT01246518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01246518.